SEC Tracker
Get the app

Eikon Therapeutics EIKN

Eikon Therapeutics presents data on EIK1003

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. EIK1003 showed favorable tolerability in combination with abiraterone in prostate cancer.
  2. ORR of 14.3% in EIK1003 monotherapy for HRR-mutated cancers.
  3. EIK1003 combined with paclitaxel showed antitumor activity in ovarian and breast cancers.
  4. No treatment-related deaths reported in any cohort.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Eikon Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Adaptimmune Therapeutics ADAP
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.